US FDA Discovers Asthma Drug May Impact Mental Health
Nov 22– U.S. government researchers have discovered that Singulair, a widely prescribed asthma medication originally sold by Merck & Co, may be linked to significant mental health issues for some patients.
The study, presented in a scientific review, found that montelukast, the generic version of Singulair, interacts with several brain receptors vital for psychiatric functioning, potentially leading to serious side effects. The findings raise concerns about the drug’s safety and its impact on mental health.
Share this content:
Post Comment